The 9 analysts offering 12-month price forecasts for Intra-Cellular Therapies Inc have a median target of 59.00, with a high estimate of 88.00 and a low estimate of 40.00. The median estimate represents a +30.01% increase from the last price of 45.38.
The current consensus among 10 polled investment analysts is to Buy stock in Intra-Cellular Therapies Inc. This rating has held steady since January, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$1.01
Reporting Date Mar 02
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.